Products & Services · Gross Profit
Orenitram — Gross Profit
United Therapeutics Orenitram — Gross Profit increased by 12.2% to $128.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.1%, from $112.40M to $128.20M. Over 4 years (FY 2021 to FY 2025), Orenitram — Gross Profit shows an upward trend with a 13.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2019
Last reportedQ1 2026
Rolls up toGross Profit
How to read this metric
An increase suggests improved pricing power or lower production costs, while a decrease indicates margin compression.
Detailed definition
Calculated as the difference between total product revenue and the direct cost of sales for a specific pharmaceutical pr...
Peer comparison
Standard gross profit metric used across all industries to evaluate product-level profitability.
Metric ID:
uthr_segment_orenitram_gross_profitHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $72.40M | $80.70M | $65.00M | $77.60M | $72.60M | $81.90M | $70.60M | $80.60M | $89.40M | $86.30M | $78.90M | $97.00M | $101.20M | $105.60M | $102.10M | $112.40M | $117.20M | $124.30M | $114.30M | $128.20M |
| QoQ Change | — | +11.5% | -19.5% | +19.4% | -6.4% | +12.8% | -13.8% | +14.2% | +10.9% | -3.5% | -8.6% | +22.9% | +4.3% | +4.3% | -3.3% | +10.1% | +4.3% | +6.1% | -8.0% | +12.2% |
| YoY Change | — | — | — | — | +0.3% | +1.5% | +8.6% | +3.9% | +23.1% | +5.4% | +11.8% | +20.3% | +13.2% | +22.4% | +29.4% | +15.9% | +15.8% | +17.7% | +11.9% | +14.1% |
Range$65.00M – $128.20M
CAGR+12.8%
Avg YoY Growth+13.5%
Median YoY Growth+13.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's orenitram — gross profit?
- United Therapeutics (UTHR) reported orenitram — gross profit of $128.20M in Q1 2026.
- How has United Therapeutics's orenitram — gross profit changed year-over-year?
- United Therapeutics's orenitram — gross profit increased by 14.1% year-over-year, from $112.40M to $128.20M.
- What is the long-term trend for United Therapeutics's orenitram — gross profit?
- Over 4 years (2021 to 2025), United Therapeutics's orenitram — gross profit has grown at a 13.1% compound annual growth rate (CAGR), from $286.40M to $468.20M.
- What does orenitram — gross profit mean?
- The profit remaining from product sales after subtracting the direct costs of producing the drug.